SHIELD - A/Prof Jonathon Fanning - Wesley Research Institute

To find out whether the medication dapagliflozin can safely reduce the risk of heart-related complications in patients who experience heart injury after non-cardiac surgery.

Research Objectives

Status

Current

Recruitment

Open

Total participants required

Study location

Wesley Research Institute, St Andrew's War Memorial Hospital

Study type

Industry Sponsored

Patient group

Adults who have had non-cardiac surgery and show evidence of heart injury after surgery (known as myocardial injury after non-cardiac surgery, or MINS), identified through routine post-operative blood tests.

About this clinical trial

After surgery, some patients experience damage to the heart muscle, which can be detected by a blood test that measures a protein called troponin. This condition is known as myocardial injury after non-cardiac surgery (MINS). While MINS is common, doctors do not yet have a clear way to predict who will develop it or how best to reduce the risk of serious heart problems once it occurs.

The SHIELD Pilot study is investigating whether a medication called dapagliflozin can help reduce the risk of major heart-related complications in patients who develop MINS. Dapagliflozin is a medication already approved in Australia for the treatment of conditions such as diabetes and heart failure, and there is good reason to believe it may also be beneficial for patients with MINS.

This pilot study will help determine whether dapagliflozin is safe and effective in this setting and will inform the design of a larger future study.

Trial Information – https://anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12625000146493

  Lead investigator  
          Associate Professor Jonathon Fanning      

  Clinical trial coordinator  
          Linda Pearce      